Prostate Cancer: Current Status of Novel Molecular Imaging and Future Prospects.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: prostate cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Our mini review focuses on PSMA PET (prostate-specific membrane antigen positron emission tomography) for diagnosis of prostate cancer, especially metastatic disease, and treatment planning and monitoring. The results show that in the right setting, PSMA PET has benefits in improving outcomes for patients with prostate cancer.
Molecular imaging has become an essential component of diagnosis, treatment planning, and monitoring in prostate cancer.
APA
Wunsch DC, Turkbey B (2026). Prostate Cancer: Current Status of Novel Molecular Imaging and Future Prospects.. European urology focus, 12(1), 28-30. https://doi.org/10.1016/j.euf.2025.11.013
MLA
Wunsch DC, et al.. "Prostate Cancer: Current Status of Novel Molecular Imaging and Future Prospects.." European urology focus, vol. 12, no. 1, 2026, pp. 28-30.
PMID
41350193 ↗
Abstract 한글 요약
Molecular imaging has become an essential component of diagnosis, treatment planning, and monitoring in prostate cancer. Prostate-specific membrane antigen-targeted positron emission tomography is now the most widely used molecular imaging approach in prostate cancer. This mini review provides an overview of the status and prospects of novel molecular imaging in prostate cancer management. PATIENT SUMMARY: Recent years have seen improvements in scans for prostate cancer. Our mini review focuses on PSMA PET (prostate-specific membrane antigen positron emission tomography) for diagnosis of prostate cancer, especially metastatic disease, and treatment planning and monitoring. The results show that in the right setting, PSMA PET has benefits in improving outcomes for patients with prostate cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.